Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

This study has been completed.
Information provided by:
Bayer Identifier:
First received: April 27, 2009
Last updated: April 25, 2013
Last verified: April 2013
Patients will be recruited from those who will undergo contrast enhanced MRI. Safety and tolerability will be assessed.

Condition Intervention
Magnetic Resonance Imaging
Drug: Gadobutrol (Gadovist, BAY86-4875)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • The primary outcome measures would be safety and tolerability of Gadovist which would be measured by change in Vital signs before and after the procedure and the occurrence of serious or non-serious adverse events [ Time Frame: Up to 1 hour after MRI ]

Other Outcome Measures:
  • Magnetic field strength of MRI [ Time Frame: During the procedure ]
  • Volume of contrast agent used [ Time Frame: During the procedure ]

Biospecimen Retention:   None Retained

Enrollment: 30
Study Start Date: June 2009
Study Completion Date: January 2011
Groups/Cohorts Assigned Interventions
Group 1 Drug: Gadobutrol (Gadovist, BAY86-4875)
Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18 years old and above who will undergo contrast enhanced MRI with Gadobutrol (Gadovist)

Inclusion Criteria:

  • 18 years old and above undergoing contrast enhanced cranial or spinal MRI with Gadobutrol (Gadovist)

Exclusion Criteria:

  • History of hypersensitivity reaction to gadolinium containing contrast material
  • Hypersensitivity to any of the ingredients of Gadobutrol (Gadovist)
  • History of hypersensitivity to any other contrast agent
  • Patients with uncorrected hypokalemia
  • Pregnant and lactating women
  • Patients with severe cardiovascular diseases
  • Patients in whom MRI cannot be performed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00905879

Many Locations, Philippines
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Medical Director, Bayer HealthCare AG Identifier: NCT00905879     History of Changes
Other Study ID Numbers: 13926
GV0811PH ( Other Identifier: Company Internal )
Study First Received: April 27, 2009
Last Updated: April 25, 2013

Keywords provided by Bayer:
Magnetic Resonance Imaging (MRI)
Observational study
Gadobutrol processed this record on May 25, 2017